Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.70 |
| ▸ | CA1 known ✓ | P00915 | 16/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 16/20 | 0.45 |
| ▸ | CA4 known ✓ | P22748 | 6/20 | 0.45 |
| ▸ | CA12 known ✓ | O43570 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | EYA2 | O00167 | 1/20 | 0.70 |
| ▸ | APP | P05067 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL2406173 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL6347089 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL49459 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL887881 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL5697081 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL6347093 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL121983 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL7870390 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL59899 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL5305791 | 1.00 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102585062-A | Preparation method for nano barium sulfate/polyethylene copper intrauterine device T-type stent material | UNIV TIANJIN TECHNOLOGY | 2012-07-18 | — | — | CN | claimed |
| CN-102329149-A | Foaming agent for sound absorption foam concrete product and preparation method for foaming agent | CAI LIANG | 2012-01-25 | — | — | CN | claimed |
| JP-4664678-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-5935566-A | AVOIDING VISIBLE PARTICULATE MATTER FORMATION IN AN AQUEOUS ALFA INTERFERON FORMULATION HAVING DISODIUM DIHYDROGEN ETHYLENEDIAMINETETRAACETATE AS A CHELATING AGENT, A SORBITAN MONO-9-OCTADECENOATE POLYOXYETHYLENE GLYCOL STABILIZER | SCHERING CORPORATION (US) | 1999-08-10 | — | — | US | claimed |
| US-20240216370-A1 | TREATMENT OF CORNEAL VASCULARISATION | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2024-07-04 | — | — | US | disclosed |
| US-20230210873-A1 | FORMULATIONS OF BRINCIDOFOVIR | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2023-07-06 | — | — | US | disclosed |
| US-20230025377-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PRURITUS | HLB Therapeutics Co., Ltd. (KR) | 2023-01-26 | — | — | US | disclosed |
| EP-4106761-A1 | TREATMENT OF CORNEAL VASCULARISATION | Vestlandets Innovasjonsselskap AS (NO) | 2022-12-28 | — | — | EP | disclosed |
| EP-4103215-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PRURITUS | HLB Therapeutics Co., Ltd. (KR) | 2022-12-21 | — | — | EP | disclosed |
| CN-111335864-B | High-permeability heterogeneous sandstone reservoir steering acidification method | 西南石油大学 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021163528-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PRURITUS | LENUS THERAPEUTICS, LLC (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210213103-A1 | METHODS OF TREATING DRY EYE SYNDROME | REGENTREE, LLC (US) | 2021-07-15 | — | — | US | disclosed |
| EP-0308192-B1 | Polyarylene thioether composition and molded product of the same | KUREHA CHEMICAL IND CO LTD (JP) | 1993-12-29 | — | — | EP | disclosed |
| EP-0353188-A2 | Novel expression system | CIBA-GEIGY AG (CH) | 1990-01-31 | — | — | EP | disclosed |
| EP-0308192-A2 | Polyarylene thioether composition and molded product of the same | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-03-22 | — | — | EP | disclosed |
| EP-0278355-A2 | Novel expression system | CIBA-GEIGY AG (CH) | 1988-08-17 | — | — | EP | disclosed |
| EP-0254249-A1 | Preparation of binding factor related polypeptides | CIBA-GEIGY AG (CH) | 1988-01-27 | — | — | EP | disclosed |
| US-4619895-A | CARDIOVASCULAR DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1986-10-28 | — | — | US | disclosed |
| US-4443429-A | POLYDIALLYLSIMETHYLAMMONIUM CHLORIDE, THIMEROSAL, SORBIC ACID, PHENYLMERCURIC SALT, ETHYLENEDIAMINETETRAACETIC ACID | BAUSCH & LOMB INCORPORATED (US) | 1984-04-17 | — | — | US | disclosed |
| US-4361548-A | Contact lens disinfecting and preserving solution (polymeric) | BAUSCH & LOMB INCORPORATED (US) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210873-A1 | FORMULATIONS OF BRINCIDOFOVIR | SAMHD1, UGT2B7, HPRT1 | ACE 235/4885CA1 4878/4885CA2 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.